Compare VBNK & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VBNK | VNDA |
|---|---|---|
| Founded | 1980 | 2002 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 499.0M | 474.0M |
| IPO Year | 2021 | 2006 |
| Metric | VBNK | VNDA |
|---|---|---|
| Price | $16.33 | $6.08 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $13.00 | ★ $13.63 |
| AVG Volume (30 Days) | 42.3K | ★ 1.0M |
| Earning Date | 03-04-2026 | 02-11-2026 |
| Dividend Yield | ★ 0.45% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.64 | N/A |
| Revenue | $85,792,576.00 | ★ $216,105,000.00 |
| Revenue This Year | $37.01 | $12.01 |
| Revenue Next Year | $30.71 | $24.28 |
| P/E Ratio | $25.63 | ★ N/A |
| Revenue Growth | 7.44 | ★ 8.72 |
| 52 Week Low | $8.51 | $3.81 |
| 52 Week High | $16.99 | $9.60 |
| Indicator | VBNK | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 56.77 | 34.52 |
| Support Level | $15.88 | $6.01 |
| Resistance Level | $16.99 | $7.65 |
| Average True Range (ATR) | 0.37 | 0.45 |
| MACD | -0.05 | -0.21 |
| Stochastic Oscillator | 41.14 | 5.01 |
VersaBank is a Schedule I Canadian bank that provides mainly commercial lending and banking services to select niche markets in Canada and the United States. Its products and services include credit assets, deposits, and cybersecurity services through its wholly owned subsidiary. The bank operates through four segments: Digital Banking Canada and Digital Banking USA, both using a business-to-business model with proprietary financial technology to serve underserved markets; DRTC, which provides cybersecurity services and banking and financial technology development; and Digital Meteor, which owns proprietary technology supporting next-generation digital assets, including Real Bank Deposit Tokens (RBDTs). The majority of revenue comes from Digital Banking.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.